Results 71 to 80 of about 83,328 (323)

Retinoic Acid Reprograms Mast Cells Toward a Proinflammatory State to Enhance Antitumor Immunity

Advanced Science, EarlyView.
Proinflammatory mast cells represent an MHC‐IIhigh, cytokine‐producing mast cell subset associated with improved survival and enhanced responses to anti‐PD‐1 therapy. Retinoic acid drives their polarization, enabling antigen uptake and presentation, and T cell recruitment and activation, collectively promoting adaptive anti‐tumor immunity.
Lizao Zhang, Siqi Ren, Yuhui Li, Rongxi Chen, Ling Qiu, Yongmei Tan, Suling Chen, Huiqian Wu, Lianxi Mai, Xiao Tan, Xin Liu, Peisheng Liang, Shijia Kuang, Liansheng Wang, Jingkang Liu, Jintao Li, Yanyan Li, Qiuping Xu, Yongzhi Su, Yuehai Luo, Binyan Wu, Zijing Huang, Haotian Cao, Qunxing Li, Jinsong Li, Tianjun Lan   +25 more
wiley   +1 more source

Ipilimumab-Induced Neutropenia in Melanoma

Journal of Investigative Medicine High Impact Case Reports, 2016
Ipilimumab is a human monoclonal IgG1 antibody against CTLA-4 that has been shown to prolong the overall survival of advanced melanoma. The most common adverse events associated with ipilimumab are immune-related.
Makiko Ban-Hoefen MD, Richard Burack MD, Lynn Sievert NP, Deepak Sahasrabudhe MD   +3 more
doaj   +1 more source

Nivolumab plus ipilimumab in the treatment of advanced melanoma. [PDF]

, 2015
Advanced melanoma has historically been a difficult disease to treat due to few effective systemic treatment options. However, over the past few years, scientific advancements in immune checkpoint inhibition have resulted in several novel approaches that
Daud, Adil I, Tsai, Katy K
core   +1 more source

The Role of Palliative Surgery for Malignant Bowel Obstruction and Perforation in Advanced Microsatellite Instability-High Colorectal Carcinoma in the Era of Immunotherapy: Case Report. [PDF]

, 2020
The role of palliative surgery in the management of acute complications in patients with disseminated malignancy remains controversial given the complexity of assessing acute surgical risk and long-term oncologic outcome. With the emergence of checkpoint
Bold, Richard J, Canter, Robert J, Cho, May, Fakih, Marwan, Gangi, Alexandra, Gholami, Sepideh, Gong, Jun, Ji, Jingran, Judge, Sean J, Kaur, Manmeet, Kim, Edward, Kirane, Amanda R, Liu, James, Tam, Kit W   +13 more
core  

Anti-CTLA-4 (CD 152) monoclonal antibody-induced autoimmune interstitial nephritis [PDF]

, 2009
Targeted immune-modulating agents are entering clinical practice in many specialties, providing novel therapeutic possibilities but introducing new potential toxicities.
Clatworthy, Menna R, Farrington, Ken, Jolly, Elaine C, Lawrence, Christopher, Nathan, Paul D   +4 more
core   +2 more sources

A Novel FGFR3‐Targeting Antibody‐Drug Conjugate Induces Tumor Cell Apoptosis through the cGAS–STING Pathway in Bladder Cancer

Advanced Science, EarlyView.
LZU‐WZLYCS01 is a novel FGFR3‐targeting ADC for bladder cancer with 7‐ethyl‐9‐fluorocamptothecin (A2) as its cytotoxic payload. LZU‐WZLYCS01 intracellularly releases A2, which targets MAD2L1 to activate the cGAS‐STING pathway and induce tumor cell apoptosis.
Shu Cui, Xiongfei Luo, Guangrui Fan, Jingqi Jiang, Yingru Wang, Enguang Yang, Jinpeng Ma, Ze Zhang, Yuhan Wang, Juan Wang, Dengtuo Wang, Hanzhang Wang, Liang Cheng, Junqiang Tian, Zhilong Dong, Yingqian Liu, Zhiping Wang   +16 more
wiley   +1 more source

Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program [PDF]

, 2019
Background: The Italian Renal Cell Cancer Early Access Program was an expanded access program that allowed access to nivolumab, for patients (pts) with metastatic renal cell carcinoma (mRCC) prior to regulatory approval.
Buti, S, Cappuzzo, F, Cartenì, G, Cognetti, F, Cortesi, E, De Giglio, A, De Giorgi, U, Giannarelli, D, Panni, S, Pazzola, A, Porta, C, Procopio, G, Raimondi, A, Rastelli, F, Rossetti, S, Sabbatini, R, Sobrero, A, Sternberg, Cn, Surico, G, Tassinari, D, Tortora, G, Turci, D, Verzoni, E   +22 more
core   +3 more sources

Functional, Pharmacogenomic, and Immune Landscapes of Long Non‐Coding RNAs in Cancer

Advanced Science, EarlyView.
A systematic analysis of 33 cancer types reveals widespread associations between lncRNAs and cancer pathways, drug responses, immune features, and immunotherapy outcomes. The study identifies key lncRNAs linked to therapeutic response and adverse events and introduces PILNC, an interactive web portal for exploring the functional, pharmacogenomic, and ...
Runhao Wang, Mei Luo, Yuan Liu, Jingwen Yang, Yamei Chen, Chengxuan Chen, Lifei Ma, Stephanie Ding, James Wengler, Yong Zang, Bora Lim, Wenbo Li, Liuqing Yang, Chunru Lin, Lixia Diao, Leng Han   +15 more
wiley   +1 more source

Cost-effectiveness of first line nivolumab-ipilimumab combination therapy for advanced non-small cell lung cancer: A systematic review and methodological quality assessment [PDF]

, 2023
Remziye Zaim, Ken Redekop, Carin A. Uyl‐de Groot   +2 more
openalex   +1 more source

SAINT: A Phase I/Expanded Phase II Study Using Safe Amounts of Ipilimumab, Nivolumab and Trabectedin as First-Line Treatment of Advanced Soft Tissue Sarcoma

Cancers, 2023
Simple Summary The SAINT study is an early-stage clinical trial based on the hypothesis that immunotherapy is more effective when given earlier in the course of the disease in patients with advanced soft tissue sarcoma. It consists of two parts.
E. Gordon, S. Chawla, W. A. Tellez, Elan Younesi, Sonu Thomas, V. Chua-Alcala, Hripsime Chomoyan, Chrysler Valencia, D. Brigham, A. Moradkhani, D. Quon, Amor M. Srikureja, Steven G. Wong, William Tseng, N. Federman   +14 more
semanticscholar   +1 more source